We are glad to now announce that GaeaOÜ has opened a Gaea Asia Pacific (APAC) office (www.gaea-apac.com) in Seoul, South Korea on June, 2021.
Gaea APAC Inc. was founded by Nigel G Goodman, CEO at GaeaOÜ and Dr. Charles JH Kim and currently they are conducting a Phase1 Head & Neck cancer study in Korea and preparing and consulting for a Korean client’s MRCTC project.
Asia region is an emerging pharmaceutical market, also well known for the dynamic nature of its potential market size and rapid growth.
Most of CROs open a branch office in Singapore but Gaea opened in Seoul, S. Korea due to the growing multinational clinical trial (2016-2018, CAGR: 1.4%) high technology hospitals and S. Korean Government support.
It’s getting hard to conduct traditional clinical trials due to the repeated lock-downs from COVID-19 but Korea still has good patient recruitment, protocol compliance and a fast regulatory review – approval system.
Korean FDA (Ministry of Food and Drug Safety, MFDS) can review and accept the clinical trials material written in English. So when considering to conduct a MRCT, Korea is a key region.
Gaea APAC will expand coverage in the South-East Asia region (Singapore, Malaysia, Thailand etc.) after stabilization of the COVID-19 situation.
Are you planning a multinational clinical trial and wish to include Korea?
We always open to support you with good timelines – and quality in drug and device clinical trials.
Dr. Charles JH Kim / 김 준 형
Respective Representative Director, Co-founder at Gaea APAC Inc.
2F 21, Teheran-ro 128, Gangnam-gu, Seoul, South Korea (zip.06234)
M. +82 10 3661 7320 Office. +82 70 4506 9110 Fax. +82 303 3442 0911
email: [email protected]